New Hampshire Trust Sells 84 Shares of Amgen Inc. (NASDAQ:AMGN)

New Hampshire Trust lowered its position in Amgen Inc. (NASDAQ:AMGNFree Report) by 1.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,679 shares of the medical research company’s stock after selling 84 shares during the period. New Hampshire Trust’s holdings in Amgen were worth $1,348,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of AMGN. Roundview Capital LLC raised its stake in shares of Amgen by 1.3% in the first quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock valued at $2,027,000 after acquiring an additional 107 shares during the last quarter. Merit Financial Group LLC raised its stake in shares of Amgen by 39.2% in the first quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock valued at $555,000 after acquiring an additional 647 shares during the last quarter. Ergoteles LLC bought a new position in shares of Amgen in the first quarter valued at approximately $219,000. First Western Trust Bank acquired a new stake in shares of Amgen in the first quarter valued at approximately $334,000. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in shares of Amgen by 2.1% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock valued at $5,970,000 after purchasing an additional 513 shares in the last quarter. Institutional investors own 74.44% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research reports. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Tuesday. Morgan Stanley lowered their price target on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Oppenheimer reissued an “outperform” rating and issued a $350.00 price target on shares of Amgen in a report on Thursday, February 1st. Finally, Truist Financial reaffirmed a “buy” rating and set a $320.00 target price on shares of Amgen in a report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $295.30.

Check Out Our Latest Research Report on AMGN

Amgen Trading Down 0.3 %

Shares of NASDAQ AMGN opened at $276.17 on Friday. The company’s fifty day moving average is $292.00 and its 200-day moving average is $279.78. The stock has a market cap of $148.01 billion, a price-to-earnings ratio of 22.11, a P/E/G ratio of 2.56 and a beta of 0.58. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGNGet Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same period last year, the firm posted $4.09 earnings per share. Equities research analysts predict that Amgen Inc. will post 19.48 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.26%. Amgen’s dividend payout ratio is currently 72.06%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.